Profil News

Our expert

Dr. Lars Bochmann

Director Marketing & Business Development

January 7, 2021

Running clinical trials at Profil during pandemic times

Impact of COVID-19 on clinical trials In December 2019, China was affected by several cases of what was considered a fatal viral pneumonia (1). The numbers of affected patients were exponentially

December 17, 2020

Profil World - The clinical diabetes research newsletter - December 2020

Dear all, Greetings from Germany! I am happy to share with you the newest edition of "Profil World" - our newsletter filled with information about clinical research in diabetes and obesity. Profil

December 1, 2020

β3-adrenoceptor agonist Mirabegron – a candidate anti-obesity drug?

The β3‐adrenoceptor (β3-AR) was initially an attractive target for several pharmaceutical companies due to its high expression in rodent adipose tissue, where its activation resulted in decreased

November 17, 2020

Once-weekly basal insulin analogue in clinical development

Once-weekly basal insulin icodec treatment may offer more convenience in people with type 2 diabetes and may improve outcomes. Molecular and biological properties of once-weekly insulin icodec and

November 4, 2020

Glycaemic control in type 1 diabetes – effects of diabetes technology and socioeconomic status

The landmark trials DCCT/EDIC trials show how important good glycaemic control is for the prevention of late complications in type 1 diabetes (T1D). According to the American Diabetes Association

October 13, 2020

Profil World - The clinical diabetes research newsletter - October 2020

Dear all, Greetings from Germany! I am happy to share with you the newest edition of "Profil World" - our newsletter filled with information about clinical research in diabetes and obesity. On-demand

September 21, 2020

Free Online Seminar: Profil - the leading CRO for metabolic research

Profil continues the successful series of scientific online seminars. On October 7th, 2020 at 4 PM CEST we will air our free online seminar. The session is presented by Dr. Lars Bochmann, Director

September 8, 2020

Profil starts in-house production of tubing sets for ClampArt®, reinforcing the quality of world-class glucose clamp trials

The euglycemic, hyperinsulinemic glucose clamp is the gold standard for the determination of pharmacokinetic and pharmacodynamic (PK/PD) effects of (new) anti-diabetic drugs, in particular insulins.

August 4, 2020

The rollercoaster life of inhaled insulin

From Nektar’s award-winning technology to its later commercial failure as Pfizer’s Exubera®. Followed by new hopes for Mannkind’s Afrezza® that suffered more commercial disappointment [1,2,3,4]. The